(NASDAQ: DNTH) Dianthus Therapeutics's forecast annual revenue growth rate of 33.6% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.53%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Dianthus Therapeutics's revenue in 2025 is $6,235,000.On average, 5 Wall Street analysts forecast DNTH's revenue for 2025 to be $166,087,175, with the lowest DNTH revenue forecast at $128,500,716, and the highest DNTH revenue forecast at $210,419,922. On average, 4 Wall Street analysts forecast DNTH's revenue for 2026 to be $153,943,858, with the lowest DNTH revenue forecast at $64,250,358, and the highest DNTH revenue forecast at $220,699,980.
In 2027, DNTH is forecast to generate $547,637,926 in revenue, with the lowest revenue forecast at $64,250,358 and the highest revenue forecast at $1,701,670,732.